ABEO
ABEONA THERAPEUTICS INC.
NASDAQ · Healthcare · Biotechnology · US
$5.57
−0.36%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$5.84
From 52W high−25.34%
Volume2.71M
Market cap$318.51M
P/E (TTM)—
P/S (TTM)12.5x
Div yield—
Key dataSep 18, 2026
Open
$5.84
From 52W high
−25.34%
Volume
2.71M
Market cap
$318.51M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.7x
P/E (TTM)
—
RSI (14)
40.7
MomentumView details →
1D Return
−0.36%
YTD Return
+6.10%
SummaryUpdated Jun 1, 2026
Abeona Therapeutics Inc. (NASDAQ:ABEO) is a clinical-stage biopharmaceutical company founded in 1974 and headquartered in New York, New York. Originally incorporated as PlasmaTech Biopharmaceuticals, the company changed its name to Abeona Therapeutics in June 2015. The company specializes in developing gene and cell therapies for life-threatening rare genetic diseases. In April 2025, Abeona achieved a major milestone with the FDA approval of <b>ZEVASKYN</b>, marking the first autologous cell-based gene therapy approved for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder.
Similar companies
Latest newsMore news →
The U.S. FDA approved a drug that Abeona Therapeutics had licensed away, entitling Abeona to collect royalties.2d agoAbeona Therapeutics activated University of Florida Health in Gainesville, Florida as the eighth Qualified Treatment Center for administering its ZEVASKYN gene-modified cellular sheets.4d ago